<DOC>
	<DOCNO>NCT01623245</DOCNO>
	<brief_summary>Cardiac amyloidosis relate accumulation fibrillar protein extracellular lead disruption cardiac tissue architecture . Amyloidosis transthyretin ( TTR ) common hereditary amyloidosis remain poorly study heart . This serious deadly . The prevalence TTR amyloidosis probably underestimate hypertrophic cardiomyopathy ( HCM ) often unknown etiology lack systematic implementation myocardial biopsy side effect .</brief_summary>
	<brief_title>Prevalence Transthyretin Amyloidosis Hypertrophic Cardiomyopathy</brief_title>
	<detailed_description>A systematic screening TTR mutation within MHC would diagnose cardiac amyloidosis TTR improve care patient family . The detection disease important disease fatal new treatment prevent accumulation TTR available ( Tafamidis ) . This drug prove effective stabilize neurological damage . Depending number patient cardiac amyloidosis TTR detect , prospect begin clinical trial test effectiveness new treatment prevent increase mass leave ventricle wall objectify resonance nuclear Magnetic .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<mesh_term>Amyloid Neuropathies , Familial</mesh_term>
	<criteria>Patients cardiomyopathy define ultrasound thickness leave ventricle &gt; = 13 mm familial form &gt; = 15 mm sporadic form . Patients sign consent authorize specific blood test genetic sequencing look abnormal TTR gene Patients diagnosis cardiomyopathy already determine relate already diagnose . Significant aortic stenosis ( ≤ 1 cm ² )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>